Start Date
January 1, 2020
Primary Completion Date
January 1, 2020
Study Completion Date
January 1, 2020
LY3200882
Combination treatment with LY3200882 and capecitabine
Collaborators (1)
Vall d'Hebron Institute of Oncology
OTHER
Agendia
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Azienda Ospedaliera Niguarda Cà Granda
OTHER
Fundación para la Investigación del Hospital Clínico de Valencia
OTHER
University of Campania Luigi Vanvitelli
OTHER
University of Turin, Italy
OTHER
Eli Lilly and Company
INDUSTRY
Catalan Institute of Health
OTHER_GOV
Universitaire Ziekenhuizen KU Leuven
OTHER
The Netherlands Cancer Institute
OTHER